AKT2 and breast carcinoma: On a sample of 402 ER-α positive breast cancer patients, Kirkergaard et al showed significantly longer survival in a group with tumours presenting strong cytoplasmic expression of Akt2 (HR 1.8, CI 95% 1.14–2.97, P=0.0115) (23).